Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.60 |
| ▸ | GSR | P00390 | 2/20 | 0.60 |
| ▸ | GRM8 | O00222 | 2/20 | 0.60 |
| ▸ | GRM6 | O15303 | 2/20 | 0.60 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.60 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.60 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.60 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.60 |
| ▸ | GRM5 | P41594 | 1/20 | 0.60 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.60 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.60 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.60 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.60 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.60 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.60 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.60 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.60 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17724321 | 1.00 | SLC1A1 (0.60) | SLC1A1GSRGRM8GRM6GRM7 | |
| SCHEMBL6384113 | 0.89 | GSR (0.48) | SLC1A1GSRGRM8GRM6GRM7 | |
| SCHEMBL16592169 | 0.87 | GSR (0.52) | SLC1A1GSRGRM8GRM6GRM7 | |
| SCHEMBL10932186 | 0.84 | SLC1A1 (0.62) | SLC1A1GSRGRM8GRM6GRM7 | |
| SCHEMBL27970765 | 0.82 | SLC1A1 (0.60) | SLC1A1GSRGRM8GRM6GRM7 | |
| SCHEMBL648219 | 0.82 | SLC1A1 (0.38) | SLC1A1GSRGRM8GRM6GRM7 | |
| SCHEMBL28203156 | 0.82 | SLC1A1 (0.60) | SLC1A1GSRGRM8GRM6GRM7 | |
| SCHEMBL28015254 | 0.82 | SLC1A1 (0.60) | SLC1A1GSRGRM8GRM6GRM7 | |
| SCHEMBL1373976 | 0.82 | SLC1A1 (0.38) | SLC1A1GSRGRM8GRM6GRM7 | |
| SCHEMBL2162458 | 0.82 | SLC1A1 (0.60) | SLC1A1GSRGRM8GRM6GRM7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115531335-B | Oselta phosphate Wei Kou disintegrating tablet and preparation method thereof | 合肥医工医药股份有限公司 | 2024-01-30 | — | — | CN | claimed |
| CN-117310064-A | Method for detecting 21 free amino acids in tea leaves | 西北农林科技大学 | 2023-12-29 | — | — | CN | claimed |
| CN-114634460-A | Process for preparing carboxyanhydrides | 北京大学 | 2022-06-17 | — | — | CN | claimed |
| JP-61141878-A | — | — | None | — | — | JP | disclosed |
| EP-3704101-B1 | COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING SAME | SERVIER LAB (FR) | 2026-05-06 | — | — | EP | disclosed |
| US-20260007647-A1 | THERAPY FOR TREATING MALIGNANCIES | SERVIER PHARMACEUTICALS LLC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250378926-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4647076-A2 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Les Laboratoires Servier (FR) | 2025-11-12 | — | — | EP | disclosed |
| US-12433895-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2025-10-07 | — | — | US | disclosed |
| EP-3984997-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER LAB (FR) | 2025-07-30 | — | — | EP | disclosed |
| CN-119421712-A | Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis | 普林斯匹亚生物制药公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20030172698-A1 | Organic nitrogen-containing composition and fertilizer comprising the same | AJINOMOTO CO., INC. (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1233071-A2 | Organic nitrogen-containing composition and fertilizer comprising the same | Ajinomoto Co., Ltd. (JP) | 2002-08-21 | — | — | EP | disclosed |
| US-5880097-A | Tethered prodrugs | TERRAPIN TECHOLOGIES, INC. (US) | 1999-03-09 | — | — | US | disclosed |
| EP-0873355-A1 | TETHERED PRODRUGS BY VIRTUE OF COVALENT LINKAGE WITH ANALOGS OF GLUTATHIONE | TERRAPIN TECHNOLOGIES, INC. (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997025342-A1 | TETHERED PRODRUGS BY VIRTUE OF COVALENT LINKAGE WITH ANALOGS OF GLUTATHIONE | TERRAPIN TECHNOLOGIES, INC. (US) | 1997-07-17 | — | — | WO | disclosed |
| JP-S61141878-A | AMMONIA ANALYZER | SHIMADZU CORP | 1986-06-28 | — | — | JP | disclosed |
| EP-0045569-B1 | METHOD FOR IMPROVING SPECIFIC XANTHAN PRODUCTIVITY DURING CONTINUOUS FERMENTATION | Standard Oil Company (US) | 1984-10-10 | — | — | EP | disclosed |
| EP-0045569-A1 | Method for improving specific xanthan productivity during continuous fermentation | Standard Oil Company (US) | 1982-02-10 | — | — | EP | disclosed |
| US-4311796-A | CULTURES, XANTHOMONAS | STANDARD OIL COMPANY (INDIANA) (US) | 1982-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250378926-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | SLC1A1 1284/4885GSR 3919/4885GRM8 3348/4885 |
| US-12433895-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | SLC1A1 4403/4885GSR 698/4885GRM8 3285/4885 |
| US-20260007647-A1 | THERAPY FOR TREATING MALIGNANCIES | DNMT3A, IDH1, TET2 | SLC1A1 1415/4885GSR 4419/4885GRM8 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.